PBX1 and acute lymphoblastic leukemia: High sensitivities to dasatinib were seen for T cell ALL (LC50 0.20, P < 0.001 compared to non-T cell ALL), TCF3-PBX1 (LC50 0.28, P = 0.013 compared to non-TCF3-PBX1; Fig. 2b) and BCR-ABL1 (LC50 0, P < 0.001 compared to non-BCR-ABL1), consistent with previous findings by us and others35,36.